Various meningococcal conjugate vaccines exist against serogroups A, C, W and Y. A new protein-based vaccine targeting serogroup B (MenB) is also now available. The potential of such vaccines to drive serogroup replacement is considered a possible public health concern when implementing nationwide routine immunization programmes. The aim of this work was to investigate if and how serogroup replacement may occur following widespread vaccination with a MenB vaccine that may protect against carriage. To that end, we built a dynamic transmission model with age and serogroup stratification, focusing on European settings where most invasive meningococcal disease (IMD) cases are caused by serogroups B and C. For illustration purposes, the model was employed in 2 such settings: UK (England and Wales) and Czech Republic. Preliminary model-based projections suggest that, under strong serogroup competition for colonization, vaccine-induced serogroup replacement may occur even with a relatively low vaccine efficacy against serogroup B carriage (e.g., 20%), with potential subsequent increase in serogroup C IMD. The magnitude and speed of the model-projected serogroup C IMD increase depend on the MenB vaccination strategy, vaccine efficacy against carriage and the extent of any potential cross-protection against other serogroups. These analyses are neither exhaustive nor definitive, and focused on simulating potential population-level trends in IMD post-vaccination, under certain assumptions. Due to present inherent limitations and uncertainties, this study has limited quantitative value and is best regarded as an explorative qualitative modeling approach, to complement and challenge the current status quo, and suggest areas where collecting additional data may be essential.

b GSK Vaccines; Vaccine Value and Health Science Epidemiology ; Wavre Belgium

c Present affiliation GSK Vaccines; Health Outcomes ; Philadelphia PA USA

GSK Vaccines; Vaccine Value and Health Science Epidemiology ; Philadelphia PA USA

See more in PubMed

Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057; http://dx.doi.org/10.1016/S1473-3099(10)70251-6 PubMed DOI

ECDC, 2013 Annual epidemiological report Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Available at: http://www.ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2013.pdf [Accessed 10 February 2015].

Soriano-Gabarro M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011; 9:761-74; PMID:21905785; http://dx.doi.org/10.1586/eri.11.89 PubMed DOI

Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother 2014; 10:995-1007; PMID:24500529; http://dx.doi.org/10.4161/hv.27739 PubMed DOI PMC

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-28; PMID:23515099 PubMed

Martin NG, Snape MD. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines 2013; 12:837-58; PMID:23984957; http://dx.doi.org/10.1586/14760584.2013.814862 PubMed DOI

Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010; 10:112-24; PMID:20113980; http://dx.doi.org/10.1016/S1473-3099(09)70324-X PubMed DOI

Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012; 30 Suppl 2:B87-97; PMID:22607904; http://dx.doi.org/10.1016/j.vaccine.2012.01.033 PubMed DOI PMC

Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61; PMID:19538112; http://dx.doi.org/10.1586/erv.09.48 PubMed DOI PMC

Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829-31; PMID:12044380; http://dx.doi.org/10.1016/S0140-6736(02)08679-8 PubMed DOI

Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al.. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014; 384:2123-31; PMID:25145775; http://dx.doi.org/10.1016/S0140-6736(14)60842-4 PubMed DOI

Bexsero: Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002333/WC500137881.pdf [Accessed 10 February 2015].

Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, et al.. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013; 13:416-25; PMID:23414709; http://dx.doi.org/10.1016/S1473-3099(13)70006-9 PubMed DOI

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al.. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573-82; PMID:22318278; http://dx.doi.org/10.1001/jama.2012.85 PubMed DOI

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, et al.. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617-24; PMID:22260988; http://dx.doi.org/10.1016/S0140-6736(11)61713-3 PubMed DOI

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381:825-35; PMID:23324563; http://dx.doi.org/10.1016/S0140-6736(12)61961-8 PubMed DOI

Claus H, Borrow R, Taha M-K, Hong E, Gilchrist S, Findlow J, Lucidarme J, Orlandi L, Rigat F, Serruto D, et al.. Potential coverage of the 4CMenB vaccine in non-B meningococci. XVIIIth International Pathogenic Neisseria Conference (IPNC) Würzburg, Germany, 2012.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760-8; PMID:21621466; http://dx.doi.org/10.1016/S1473-3099(11)70090-1 PubMed DOI

Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 2006; 5:651-67; PMID:17181439; http://dx.doi.org/10.1586/14760584.5.5.651 PubMed DOI

Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005; 162:89-100; PMID:15961591; http://dx.doi.org/10.1093/aje/kwi160 PubMed DOI

Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013; 31:2638-46; PMID:23566946; http://dx.doi.org/10.1016/j.vaccine.2013.03.034 PubMed DOI PMC

Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 2010; 10:90; PMID:20377886; http://dx.doi.org/10.1186/1471-2334-10-90 PubMed DOI PMC

Van Effelterre T, Moore MR, Fierens F, Whitney CG, White L, Pelton SI, Hausdorff WP. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 2010; 28:3650-60; PMID:20359560; http://dx.doi.org/10.1016/j.vaccine.2010.03.030 PubMed DOI

Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al.. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43; PMID:18271745; http://dx.doi.org/10.1086/527401 PubMed DOI PMC

Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007; 31:52-63; PMID:17233635; http://dx.doi.org/10.1111/j.1574-6976.2006.00052.x PubMed DOI

Krizova P, Kalmusova J, Musilek M, Felsberg J, Haugvicova R, Vlckova J. [Study of long-term and multiple carriage of Neisseria meningitidis in a healthy population using molecular biology methods]. Epidemiol Mikrobiol Imunol 2004; 53:25-36; PMID:15052832 PubMed

Martcheva M, Pilyugin SS, Holt RD. Subthreshold and superthreshold coexistence of pathogen variants: the impact of host age-structure. Math Biosci 2007; 207:58-77; PMID:17087980; http://dx.doi.org/10.1016/j.mbs.2006.09.010 PubMed DOI

Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010; 10:175; PMID:20565757; http://dx.doi.org/10.1186/1471-2334-10-175 PubMed DOI PMC

Bettinger JA, Deeks SL, Halperin SA, Tsang R, Scheifele DW. Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines 2013; 12:505-17; PMID:23659299; http://dx.doi.org/10.1586/erv.13.30 PubMed DOI

Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, Alvestad T, Jolley KA, Wilson DJ, McCarthy ND, et al.. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004; 42:5146-53; PMID:15528708; http://dx.doi.org/10.1128/JCM.42.11.5146-5153.2004 PubMed DOI PMC

Bogaert D, Hermans PW, Boelens H, Sluijter M, Luijendijk A, Rumke HC, Koppen S, van Belkum A, de Groot R, Verbrugh HA. Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children. Clin Infect Dis 2005; 40:899-902; PMID:15736029; http://dx.doi.org/10.1086/428351 PubMed DOI

Leimkugel J, Hodgson A, Forgor AA, Pfluger V, Dangy JP, Smith T, Achtman M, Gagneux S, Pluschke G. Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med 2007; 4:e101; PMID:17388665; http://dx.doi.org/10.1371/journal.pmed.0040101 PubMed DOI PMC

Frosch M, Maiden MCJ. Handbook of meningococcal disease : infection biology, vaccination, clinical management Germany: Weinheim: : Wiley-VCH, 2008.

Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, et al.. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5:e74; PMID:18366252; http://dx.doi.org/10.1371/journal.pmed.0050074 PubMed DOI PMC

Goeyvaerts N, Hens N, Ogunjimi B, Aerts M, Shkedy Z, Damme PV, Beutels P. Estimating infectious disease parameters from data on social contacts and serological status. J Royal Statist Soc Series C: Applied Statistics 2010; 59:255-77; http://dx.doi.org/10.1111/j.1467-9876.2009.00693.x DOI

Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol 2006; 164:936-44; PMID:16968863; http://dx.doi.org/10.1093/aje/kwj317 PubMed DOI

Lipsitch M, Colijn C, Cohen T, Hanage WP, Fraser C. No coexistence for free: neutral null models for multistrain pathogens. Epidemics 2009; 1:2-13; PMID:21352747; http://dx.doi.org/10.1016/j.epidem.2008.07.001 PubMed DOI PMC

Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006; 134:556-66; PMID:16238823; http://dx.doi.org/10.1017/S0950268805005339 PubMed DOI PMC

Ogunjimi B, Hens N, Goeyvaerts N, Aerts M, Van Damme P, Beutels P. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. Math Biosci 2009; 218:80-7; PMID:19174173; http://dx.doi.org/10.1016/j.mbs.2008.12.009 PubMed DOI

Sutton KL, Banks HT, Castillo-Chavez C. Public vaccination policy using an age-structured model of pneumococcal infection dynamics. J Biol Dyn 2010; 4:176-95; PMID:22876985; http://dx.doi.org/10.1080/17513750903023715 PubMed DOI

Coen PG, Cartwright K, Stuart J. Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica. Int J Epidemiol 2000; 29:180-8; PMID:10750621; http://dx.doi.org/10.1093/ije/29.1.180 PubMed DOI

Wise J. Meningitis B vaccine to be introduced in UK after U turn on its cost effectiveness. BMJ 2014; 348:g2327; PMID:24665138; http://dx.doi.org/10.1136/bmj.g2327 PubMed DOI

Health Protection Agency Laboratory confirmed cases of all invasive meningococcal disease by serogroup, age and epidemiological year, England and Wales. Available at: https://www.gov.uk/government/collections/meningococcal-disease-guidance-data-and-analysis [Accessed 10 February 2015].

Hogea C, Effelterre TV, Vyse A, Kriz P, Soriano-Gabarró M. Neisseria meningitidis: A baseline dynamic transmission model for the Czech Republic. 28th Annual ESPID Meeting; Nice, France; 2010.

UK's Office for National Statistics Population Estimates by Age and Sex. Available at: http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population +Estimates+by+Age+and+Sex [Accessed 10 February 2015].

Czech Statistical Office Czech Demagraphic Handbook 2007. Available at: http://csugeo.i-server.cz/csu/2008edicniplan.nsf/engpubl/4032-08-2007 [Accessed 10 February 2015].